Medpace Holdings, Inc. $MEDP Stock Purchased by Vise Technologies Inc.

Vise Technologies Inc. boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 99.4% in the 3rd quarter, Holdings Channel reports. The firm owned 2,291 shares of the company’s stock after buying an additional 1,142 shares during the quarter. Vise Technologies Inc.’s holdings in Medpace were worth $1,430,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Novem Group grew its stake in shares of Medpace by 1.0% in the third quarter. Novem Group now owns 2,127 shares of the company’s stock valued at $1,328,000 after buying an additional 22 shares in the last quarter. Fifth Third Wealth Advisors LLC raised its holdings in shares of Medpace by 3.2% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 783 shares of the company’s stock valued at $489,000 after buying an additional 24 shares during the period. Balefire LLC lifted its position in Medpace by 6.1% during the 1st quarter. Balefire LLC now owns 451 shares of the company’s stock worth $217,000 after acquiring an additional 26 shares in the last quarter. Motley Fool Asset Management LLC lifted its position in Medpace by 3.3% during the 3rd quarter. Motley Fool Asset Management LLC now owns 819 shares of the company’s stock worth $511,000 after acquiring an additional 26 shares in the last quarter. Finally, GAMMA Investing LLC lifted its position in Medpace by 2.8% during the 2nd quarter. GAMMA Investing LLC now owns 1,158 shares of the company’s stock worth $613,000 after acquiring an additional 32 shares in the last quarter. 77.98% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on MEDP shares. Robert W. Baird set a $699.00 price target on Medpace in a report on Friday, October 23rd. Weiss Ratings upgraded shares of Medpace from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Truist Financial boosted their target price on shares of Medpace from $609.00 to $633.00 and gave the stock a “hold” rating in a research report on Friday, October 23rd. Jefferies Financial Group restated a “hold” rating on shares of Medpace in a research note on Monday, September 14th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price target on shares of Medpace in a report on Thursday, July 23rd. Three equities research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $649.27.

Medpace Stock Performance

Shares of NASDAQ MEDP traded up $18.13 during midday trading on Friday, reaching $653.11. 231,622 shares of the company’s stock were exchanged, compared to its average volume of 326,140. Medpace Holdings, Inc. has a 52-week low of $373.00 and a 52-week high of $693.97. The stock has a market capitalization of $18.27 billion, a PE ratio of 36.20, a price-to-earnings-growth ratio of 2.51 and a beta of 1.12. The business’s fifty day moving average price is $622.54 and its two-hundred day moving average price is $532.32.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, October 21st. The company reported $4.84 EPS for the quarter, beating analysts’ consensus estimates of $4.44 by $0.40. Medpace had a return on equity of 99.76% and a net margin of 18.24%. The firm had revenue of $716.00 million during the quarter, compared to the consensus estimate of $714.47 million. During the same quarter in the prior year, the business posted $3.86 earnings per share. Medpace’s revenue for the quarter was up 8.5% on a year-over-year basis. Analysts predict that Medpace Holdings, Inc. will post 18.06 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO August Troendle sold 49,018 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $628.11, for a total transaction of $30,788,695.98. Following the completion of the transaction, the chief executive officer directly owned 433,372 shares in the company, valued at approximately $272,205,286.92. This represents a 10.16% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, VP Susan Burwig sold 16,060 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The stock was sold at an average price of $677.00, for a total transaction of $10,872,620.00. Following the sale, the vice president directly owned 57,624 shares of the company’s stock, valued at $39,011,448. The trade was a 21.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 342,647 shares of company stock worth $213,561,374. 20.50% of the stock is currently owned by corporate insiders.

Medpace Profile

Medpace Holdings, Inc is a contract research organization (CRO) that provides clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports sponsors throughout the development process, from early-stage planning and regulatory submissions through clinical trial execution, data management, analysis and reporting.

Medpace’s services include Phase I through Phase IV clinical research, clinical monitoring, biostatistics, data management, medical writing, pharmacovigilance, regulatory consulting and central laboratory services.